Other languages Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Market Closed - OTC Markets Other stock markets 20:38:43 07/06/2024 BST			5-day change	1st Jan Change
0.0799 ^USD	-17.54%		-19.29%	-53.79%

04-16	Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	CI
03-19	Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	04-16
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	03-19
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	02-06
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	22/08/23
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	18/08/23
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	02/07/23
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29/06/23
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	30/05/23
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	28/02/23
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	25/01/23
Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer Trial	10/01/23
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board	20/12/22
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22
Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research	04/10/22
Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer	13/09/22
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	15/06/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Other languages

Filters